Volume 26, Number 10—October 2020
Effectiveness of 23-Valent Pneumococcal Polysaccharide Vaccine against Invasive Pneumococcal Disease in Adults, Japan, 2013–2017
|Age group, y|| Adjusted VE,† % (95% CI)
||p value by test for interaction|
|Overall||47.1 (−4.7 to 73.3)||39.3 (−2.9 to 64.2)||0.953|
|20–64||77.1 (−110.4 to 97.5)||41.0 (−128.8 to 84.8)||0.124|
|>65||39.9 (−28.4 to 71.9)||39.4 (−6.1 to 65.3)||0.809|
*BMI, body mass index; PPSV23, 23-valent pneumococcal polysaccharide vaccine; VE, vaccine effectiveness.
†Adjusted for sex, age, prefecture, year, season, BMI group, underlying conditions, and smoking history with clustering by public health center.
Page created: August 05, 2020
Page updated: September 17, 2020
Page reviewed: September 17, 2020
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.